Daniel Elbirt
Overview
Explore the profile of Daniel Elbirt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
306
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trottier B, Yang C, Watanabe D, Marchetti G, Elbirt D, de Barra E, et al.
HIV Res Clin Pract
. 2025 Feb;
26(1):2456890.
PMID: 39936702
Background: BICtegravir Single Tablet Regimen (BICSTaR) is an observational cohort study evaluating the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve (TN) and treatment-experienced (TE) people with HIV. Objective:...
2.
Nemet S, Elbirt D, Cohen R, Mahlab-Guri K, Bezalel-Rosenberg S, Asher I, et al.
J Allergy Clin Immunol Glob
. 2025 Feb;
4(2):100403.
PMID: 39931077
Background: Very high serum IgE (≥1000 IU/mL) is reported in atopic disorders. However, data on its significance in nonallergic disorders are limited. Objective: We aimed to analyze the diagnostic value...
3.
Wagner T, Levy I, Wieder-Finesod A, Wax M, Gozlan Y, Elbirt D, et al.
AIDS
. 2025 Feb;
PMID: 39912770
Objective: Assess virological failures, analyze the results of resistance testing (RET), and investigate factors associated with acquired drug resistance mutations (aDRM). Design: A retrospective longitudinal cohort study. Methods: Virological failures...
4.
Mahlab-Guri K, Komarova I, Kadar L, Nemet S, Cohen R, Radian-Sade S, et al.
Viruses
. 2025 Jan;
16(12.
PMID: 39772116
Introduction: Variants of COVID-19 are responsible for 700 million infections and 7 million deaths worldwide. Vaccinations have high efficiency in preventing infection and secondary benefits of reducing COVID-19 hospital admissions,...
5.
6.
Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, et al.
Clin Infect Dis
. 2024 Apr;
79(5):1242-1257.
PMID: 38663013
Background: Mortality among people with human immunodeficiency virus (HIV) declined with the introduction of combination antiretroviral therapy. We investigated trends in mortality in people with HIV from 1999 through 2020....
7.
Maman O, Abu Ahmad W, Perzon O, Mahlab-Guri K, Elbirt D, Elinav H
BMC Infect Dis
. 2024 Feb;
24(1):221.
PMID: 38373940
Objective: This study aimed to assess weight gain associated with treatment switching to INSTI-based regimens in people living with HIV (PLWH) and to determine whether it is accompanied by worsening...
8.
Nemet S, Elbirt D, Mahlab-Guri K, Bezalel-Rosenberg S, Asher I, Talmon A, et al.
Pediatr Allergy Immunol
. 2023 Dec;
34(12):e14061.
PMID: 38146117
Background: Accumulating evidence suggests that food-induced anaphylaxis (FIA) may induce different psychological disorders (PDs). In this study, we aimed to further evaluate the effect of FIA, specifically when occurring in...
9.
Wagner T, Levy I, Elbirt D, Shahar E, Olshtain-Pops K, Elinav H, et al.
Viruses
. 2023 Dec;
15(12).
PMID: 38140680
Despite the progress in contemporary antiretroviral therapy (ART) and the continuous changes in treatment guidelines, virological failure (VF) is still an ongoing concern. The goal of this study was to...
10.
Mahlab-Guri K, Mishayev D, Yakovlev M, Asher I, Sthoeger Z, Guri A, et al.
Immunotherapy
. 2023 Sep;
15(16):1389-1400.
PMID: 37694383
Despite their life-threatening potential, medical team mistakes during subcutaneous immunotherapy are rarely discussed. Real data are missing, and a survey study estimated that dosing errors are responsible for 25% of...